|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Studies on the pharmacokinetics of contraceptive steroids under steady-state |
| conditions. [Untersuchungen zur Pharmakokinetik kontrazeptiver Steroide |
| unter den Bedingungen der Langzeiteinnahme.] |
| Carol W; Klinger G; Michels W; Boer J; Pocha C |
| ZENTRALBLATT FUR GYNAKOLOGIE. 1991;113(23):1298-303. |
| Pharmacokinetic investigations (c0h, c2h, c6h, c24h, AUC24) were carried out both in the 1st and last 4 days of a |
| treatment cycle in patients of different ages who used oral contraceptives (OCs) for at least 12 months. 57 women |
| took the preparation Trisiston (3-step formulation with the components 0.03 mg ethinyl estradiol [EE2] + 0.05 mg |
| levonorgestrel [LNG], 0.04 mg EE2 + 0.075 LNG, 0.03 mg EE2 + 0.125 mg LNG). 23 subjects used Gravistat (0.05 |
| mg EE2 + 0.125 mg LNG) and 17 patients took Certostat, a preparation still in clinical evaluation (0.05 mg EE2 + 2.0 |
| mg Dienogest [DNG]). The levels of EE2, LNG, and DNG were measured by means of radioimmunoassays. Between |
| the concentrations obtained after administration of a 1st and single tablet (earlier investigations) and those |
| determined in longtime users during the 1st 4 days following the tablet-free interval, no qualitative or quantitative |
| differences were observed. There were marked differences in levels of EE2 and LNG determined in the 1st and last |
| days of treatment when comparing Trisiston and Gravistat, but not in those taking Certostat. The conclusion is that a |
| cyclical and reversible cumulative effect emerges under the influence of LNG-containing OCs, the mechanisms of |
| which cannot be explained solely by the increase of carrier protein capacity. It seems possible that this is due to an |
| alteration of steroid metabolism resulting from the interaction between both components. (summaries in GER, |
| ENG) (PubHealth.info Document ID: CONT3T 2024-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Studies on the pharmacokinetics of contraceptive steroids |
| under steady-state conditions. [Untersuchungen zur Pharmakokinetik kontrazeptiver Steroide unter den Bedingungen |
| der Langzeiteinnahme.]", is(are) Carol W; Klinger G; Michels W; Boer J; Pocha C. The source of this article is |
| "ZENTRALBLATT FUR GYNAKOLOGIE. 1991;113(23):1298-303.". This article was published in 1991 in German |
| language(s). (PubHealth.info® Document ID: CONT3T 2024-06. All rights reserved with PubHealth.info) PIN: 12024 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
